Furthermore, the administration of MCPyV viral-like proteins (VLPs) induced a strong immune response in mice, suggesting a good requisite for the development of preventive VLP-based cancer vaccines, since VLPs can trigger a strong CD4+ T-cell-mediated immune responses against oncoviruses [60,61]. This evidence concerns the gene CD4 and cancer.